Seattle Genetics Profile |
49.57 |
|
Sale by Clay Siegall of 9000 shares of Seattle Genetics
| Seattle Genetics insider trading alert for sale of common stock by Clay Siegall, President and CEO, on April 19, 2018. This event was filed by Seattle Genetics Inc with SEC on 2005-08-02. Statement of changes in beneficial ownership - SEC Form 4. Clay Siegall is currently serves as co-founder, chairman, ceo and pres of Seattle Genetics [view details] |
Seattle Genetics Summary
Seattle Genetics (SGEN) is traded on NASDAQ in USA. It is located in WASHINGTON, U.S.A and employs 1,100 people. Seattle Genetics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 7.94 B. Seattle Genetics conducts business under Healthcare sector and is part of Biotechnology industry. This company has 157.95 M outstanding shares of which 12.74 M shares are at this time shorted by private and institutional investors with about 13.38 trading days to cover.
SEATTLE GENETICS currently holds about 413.17 M in cash with (118.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.62.
Check Seattle Genetics Probability Of Bankruptcy
Ownership Allocation (%)
Target Price Odds Analysis
| Below Odds | Horizon | Target | Above Odds |
| about 6.0% | 30 days | 49.57 | more than 94.0% |
| Based on normal probability distribution, the odds of Seattle Genetics to move above current price in 30 days from now is more than 94.0% (This Seattle Genetics probability density function shows the probability of Seattle Genetics Stock to fall within a particular range of prices over 30 days) . |
Top Holders
| Category | |||
 | Nasdaq | US Index | |
 | NYSE | US Index | |
| SPDR SP | SPDR SP Biotech ETF | MX ETF | |
| SPDR SP Biotech ETF | Sector |
Major Institutional Holders
| Instituion | Security Type | Total Shares | Value | |
| Rhenman Partners Asset Management Ab | Common Shares | 130 K | 6.8 M | |
| Gateway Investment Advisers Llc | Common Shares | 70.1 K | 3.7 M |
Key Fundamentals
| Return On Asset | (14.26) % | ||
| Profit Margin | (26.03) % | ||
| Operating Margin | (40.60) % |
Seattle Genetics Against Markets
Risk Adjusted Performance Score (0 to 100) | 0 |
Chance of | < 65% |
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington. Seattle Genetics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 1100 people. more
 |
| |||
| Name | Seattle Genetics | |||
| Chairman | Clay SiegallView All | |||
| Thematic Classification Currently Active Investing Idea |
| |||
| Analyst Consensus | ||||
| Piotroski F Score | ||||
| Macroaxis Advice | ||||
Specialization | Healthcare, Pharmaceuticals And Biosciences | |||
| Instrument | USA Stock View All | |||
| Region | North America | |||
| Location | WASHINGTON, U.S.A | |||
| Business Address | 21823 30th Drive SE | |||
| Exchange | NASDAQ | |||
| CIK Number | 01060736.0 | |||
| ISIN | US8125781026 | |||
| CUSIP | 812578102 | |||
| Sector | Healthcare | |||
| Industry | Biotechnology | |||
| Benchmark | DOW | |||
| Website | www.seattlegenetics.com | |||
| Contact Number | 425 527 4000 | |||
| Currency | USD - US Dollar |
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
| Hide View All Next | Launch Cryptocurrency Center |
Recommendations
Seattle Genetics Analyst Recommendations
| Target Price | Advice | # of Analysts | |
| 57.73 | Hold | 11 | Odds |
| Seattle Genetics Analyst Advice |
Earnings
Seattle Genetics Earnings Estimates
| EPS | Estimate Date | ||
|---|---|---|---|
| Quarterly Estimate | -0.42 | April 27, 2017 |
| Earnings Estimate |
Directors
Seattle Genetics Corporate Directors
| Pinkston Peggy Senior Director - Corporate Communications | |
| David Gryska Independent Director, MBA | |
| Daniel Welch Independent Director, MBA |
Also please take a look at World Market Map. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.